Editorial: Getting into the AKT

Journal of the National Cancer Institute

Volumn 102, Issue 11, 2010, Pages 747-749

  Brodeur, Garrett M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN RET; PROTEIN TYROSINE KINASE A; RAPAMYCIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GROWTH INHIBITOR; PHOSPHORYLCHOLINE; PROTEIN TYROSINE KINASE;

CANCER INHIBITION; EDITORIAL; ENZYME ACTIVITY; HUMAN; NEUROBLASTOMA; ONCOGENE C MYB; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; CELL SURVIVAL; CLINICAL TRIAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; NOTE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GROWTH INHIBITORS; HUMANS; MICE; NEUROBLASTOMA; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 77953219150     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq171     Document Type: Editorial

References (52)

1. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins. In press.
2. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24(18): 2891-2896.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106-2120.
4. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165-1173.
5. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203-216.
6. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55(1):97-120, x.
7. Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15(10):3244-3250.
8. Thiele C, Li Z, McKee A. On Trk\the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res. 2009;15(19):5962-5967.
9. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affnity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res. 1993;53(9):2044-2050.
10. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplifcation in human neuroblastomas. Cancer Res. 1992;52(5):1364-1368.
11. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993;328(12):847-854.
12. Nakagawara A, Brodeur GM. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur J Cancer. 1997;33(12): 2050-2053.
13. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC. Lack of high-affnity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst. 1993;85(5):377-384.
14. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol. 1994;14(1):759-767.
15. Nakagawara A, Liu XG, Ikegaki N, et al. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics. 1995;25(2):538-546.
16. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002;62(22):6462-6466.
17. Jaboin J, Hong A, Kim CJ, Thiele CJ. Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Lett. 2003;193(1):109-114.
18. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res. 2002;62(22):6756-6763.
19. Lucarelli E, Kaplan D, Thiele CJ. Activation of trk-A but not trk-B signal transduction pathway inhibits growth of neuroblastoma cells. Eur J Cancer. 1997;33(12):2068-2070.
20. Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res. 1995;55(8):1798-1806.
21. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifcations of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416(2):153-159.
22. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455(7215):971-974.
23. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215): 975-978.
24. Mosse YP, Laudenslager M, Longo L, et al. Identifcation of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215): 930-935.
25. Oppenheimer O, Cheung NK, Gerald WL. The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007; 6(4):1300-1309.
26. Cerchia L, D'Alessio A, Amabile G, et al. An autocrine loop involving ret and glial cell-derived neurotrophic factor mediates retinoic acid-induced neuroblastoma cell differentiation. Mol Cancer Res. 2006;4(7):481-488.
27. Bunone G, Borrello MG, Picetti R, et al. Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis. Exp Cell Res. 1995;217(1): 92-99.
28. Michaelis M, Bliss J, Arnold SC, et al. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specifc toxins. Clin Cancer Res. 2008;14(20):6531-6537.
29. Ho R, Minturn JE, Hishiki T, et al. Proliferation of human neuroblas-tomas mediated by the epidermal growth factor receptor. Cancer Res. 2005;65(21):9868-9875.
30. Meyers MB, Shen WP, Spengler BA, et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem. 1988;38(2):87-97.
31. Guerreiro AS, Boller D, Shalaby T, Grotzer MA, Arcaro A. Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int J Cancer. 2006;119(11):2527-2538.
32. Chambery D, Mohseni-Zadeh S, de Galle B, Babajko S. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line. Cancer Res. 1999;59(12):2898-2902.
33. Zhang L, Smith KM, Chong AL, et al. In vivo antitumor and antimeta-static activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia. 2009;11(5):426-435.
34. Beaudry P, Nilsson M, Rioth M, et al. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothe-lium. Mol Cancer Ther. 2008;7(2):418-424.
35. Evans AE, Kisselbach KD, Liu X, et al. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Med Pediatr Oncol. 2001;36(1): 181-184.
36. Evans AE, Kisselbach KD, Yamashiro DJ, et al. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xe-nografts. Clin Cancer Res. 1999;5(11):3594-3602.
37. Freeman BB III, Daw NC, Geyer JR, Furman WL, Stewart CF. Evaluation of geftinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest. 2006; 24(3):310-317.
38. Iyer R, Evans AE, Qi X, et al. Lestaurtinib enhances the antitumor effcacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res. 2010;16(5):1478-1485.
39. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase I and phar-macokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008;26(30):4921-4927.
40. Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifos-ine. J Natl Cancer Inst. 2010;102(11):760-772.
41. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261-1274.
42. Lindsley CW, Barnett SF, Layton ME, Bilodeau MT. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and al-losteric Akt kinase inhibitors. Curr Cancer Drug Targets. 2008;8(1):7-18.
43. Barnett SF, Bilodeau MT, Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Top Med Chem. 2005;5(2):109-125.
44. Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol. 2006;7(4):285-294.
45. Tazzari PL, Tabellini G, Ricci F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myeloge-nous leukemia cells. Cancer Res. 2008;68(22):9394-9403.
46. David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res. 2008;14(16):5090-5098.
47. Mitsiades CS, Hideshima T, Chauhan D, et al. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009;46(2):166-175.
48. Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006;5(7):766-770.
49. Bailey HH, Mahoney MR, Ettinger DS, et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer. 2006;107(10):2462-2467.
50. Vink SR, Schellens JH, Beijnen JH, et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol. 2006;80(2):207-213.
51. Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM Jr, Benson AB III. A phase II trial of perifosine in locally advanced, unresect-able, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007;30(1): 26-31.
52. Leighl NB, Dent S, Clemons M, et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat. 2008;108(1): 87-92.